| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $119.4M | +5.0% |
| SG&A Expense | $34.6M | +15.5% |
| Operating Income | -$154.1M | -7.2% |
| Pre-tax Income | $138.2M | +3.0% |
| Income Tax | $0 | — |
| Net Income | -$138.2M | -3.0% |
| EPS (Basic) | -$1.01 | +42.9% |
| EPS (Diluted) | -$1.01 | +42.9% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $49.5M | -78.0% |
| Current Assets | $316.5M | +19.9% |
| Total Assets | $350.1M | +17.6% |
| Current Liabilities | $30.5M | +70.2% |
| Total Liabilities | $57.0M | +20.9% |
| Stockholders' Equity | $293.1M | +17.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$118.0M | +2.6% |
| Capital Expenditures | $15K | -92.2% |
| Investing Cash Flow | -$218.8M | -409.5% |
| Financing Cash Flow | $161.2M | +19.0% |
| Free Cash Flow | -$118.0M | +2.7% |